Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel: Systematic review and meta-analysis of individual patient data

Jean Luc Reny, Pierre Fontana, Willibald Hochholzer, Franz Josef Neumann, Jurriën ten Berg, Paul W. Janssen, Tobias Geisler, Meinrad Gawaz, Rossella Marcucci, Anna Maria Gori, Thomas Cuisset, Marie Christine Alessi, Philippe Berdagué, Paul A. Gurbel, Gerald Yong, Dominick J. Angiolillo, D. Aradi, Roy Beigel, Gianluca Campo, Christophe Combescure

Research output: Article

23 Citations (Scopus)

Abstract

Prior studies have shown an association between high on-clopidogrel platelet reactivity (PR) and the risk of major adverse cardiovascular events (MACE). However, large intervention trials on PR-tailored treatments have been neutral. The role and usefulness of PR with regard to levels of cardiovascular risk are unclear. We undertook a systematic review and meta-analysis of individual patient data on MACE outcomes (acute coronary syndromes (ACS), ischaemic strokes, and vascular deaths) in relation to PR and its interaction with cardiovascular risk levels. PR was determined using ADP-induced light transmission aggregometry with a primary concentration of 20 µM ADP. Thirteen prospective studies totaled 6,478 clopidogrel-treated patients who experienced 421 MACE (6.5 %) during a median follow-up of 12 months. The strength of the association between the risk of MACE and PR increased significantly (p=0.04) with the number of risk factors present (age> 75 years, ACS at inclusion, diabetes, and hypertension). No association was detected in patients with no risk factor (p=0.48). In patients presenting one risk factor, only high-PR was associated with an increased risk of MACE (HR 3.2, p=0.001). In patients presenting ≥ 2 risk factors, the increase of risk started from medium-PR (medium-PR: HR=2.9, p=0.0004; high-PR: HR=3.7, p=0.0003). PR allowed the re-classification of 44 % of the total population to a different risk level for the outcome of MACE, mostly in intermediate or high risk patients. In conclusion, the magnitude of the association between PR and MACE risk is strongly dependent on the level of cardiovascular risk faced by patients on clopidogrel.

Original languageEnglish
Pages (from-to)844-855
Number of pages12
JournalThrombosis and Haemostasis
Volume115
Issue number4
DOIs
Publication statusPublished - ápr. 1 2016

Fingerprint

clopidogrel
Blood Vessels
Meta-Analysis
Blood Platelets
Acute Coronary Syndrome
Adenosine Diphosphate

ASJC Scopus subject areas

  • Hematology

Cite this

Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel : Systematic review and meta-analysis of individual patient data. / Reny, Jean Luc; Fontana, Pierre; Hochholzer, Willibald; Neumann, Franz Josef; ten Berg, Jurriën; Janssen, Paul W.; Geisler, Tobias; Gawaz, Meinrad; Marcucci, Rossella; Gori, Anna Maria; Cuisset, Thomas; Alessi, Marie Christine; Berdagué, Philippe; Gurbel, Paul A.; Yong, Gerald; Angiolillo, Dominick J.; Aradi, D.; Beigel, Roy; Campo, Gianluca; Combescure, Christophe.

In: Thrombosis and Haemostasis, Vol. 115, No. 4, 01.04.2016, p. 844-855.

Research output: Article

Reny, JL, Fontana, P, Hochholzer, W, Neumann, FJ, ten Berg, J, Janssen, PW, Geisler, T, Gawaz, M, Marcucci, R, Gori, AM, Cuisset, T, Alessi, MC, Berdagué, P, Gurbel, PA, Yong, G, Angiolillo, DJ, Aradi, D, Beigel, R, Campo, G & Combescure, C 2016, 'Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel: Systematic review and meta-analysis of individual patient data', Thrombosis and Haemostasis, vol. 115, no. 4, pp. 844-855. https://doi.org/10.1160/TH15-09-0742
Reny, Jean Luc ; Fontana, Pierre ; Hochholzer, Willibald ; Neumann, Franz Josef ; ten Berg, Jurriën ; Janssen, Paul W. ; Geisler, Tobias ; Gawaz, Meinrad ; Marcucci, Rossella ; Gori, Anna Maria ; Cuisset, Thomas ; Alessi, Marie Christine ; Berdagué, Philippe ; Gurbel, Paul A. ; Yong, Gerald ; Angiolillo, Dominick J. ; Aradi, D. ; Beigel, Roy ; Campo, Gianluca ; Combescure, Christophe. / Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel : Systematic review and meta-analysis of individual patient data. In: Thrombosis and Haemostasis. 2016 ; Vol. 115, No. 4. pp. 844-855.
@article{5b42de5307814cd289fb90bc8f5fd5f5,
title = "Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel: Systematic review and meta-analysis of individual patient data",
abstract = "Prior studies have shown an association between high on-clopidogrel platelet reactivity (PR) and the risk of major adverse cardiovascular events (MACE). However, large intervention trials on PR-tailored treatments have been neutral. The role and usefulness of PR with regard to levels of cardiovascular risk are unclear. We undertook a systematic review and meta-analysis of individual patient data on MACE outcomes (acute coronary syndromes (ACS), ischaemic strokes, and vascular deaths) in relation to PR and its interaction with cardiovascular risk levels. PR was determined using ADP-induced light transmission aggregometry with a primary concentration of 20 µM ADP. Thirteen prospective studies totaled 6,478 clopidogrel-treated patients who experienced 421 MACE (6.5 {\%}) during a median follow-up of 12 months. The strength of the association between the risk of MACE and PR increased significantly (p=0.04) with the number of risk factors present (age> 75 years, ACS at inclusion, diabetes, and hypertension). No association was detected in patients with no risk factor (p=0.48). In patients presenting one risk factor, only high-PR was associated with an increased risk of MACE (HR 3.2, p=0.001). In patients presenting ≥ 2 risk factors, the increase of risk started from medium-PR (medium-PR: HR=2.9, p=0.0004; high-PR: HR=3.7, p=0.0003). PR allowed the re-classification of 44 {\%} of the total population to a different risk level for the outcome of MACE, mostly in intermediate or high risk patients. In conclusion, the magnitude of the association between PR and MACE risk is strongly dependent on the level of cardiovascular risk faced by patients on clopidogrel.",
keywords = "Cardiovascular diseases, Clopidogrel, Drug response, Ischaemic events, Platelets",
author = "Reny, {Jean Luc} and Pierre Fontana and Willibald Hochholzer and Neumann, {Franz Josef} and {ten Berg}, Jurri{\"e}n and Janssen, {Paul W.} and Tobias Geisler and Meinrad Gawaz and Rossella Marcucci and Gori, {Anna Maria} and Thomas Cuisset and Alessi, {Marie Christine} and Philippe Berdagu{\'e} and Gurbel, {Paul A.} and Gerald Yong and Angiolillo, {Dominick J.} and D. Aradi and Roy Beigel and Gianluca Campo and Christophe Combescure",
year = "2016",
month = "4",
day = "1",
doi = "10.1160/TH15-09-0742",
language = "English",
volume = "115",
pages = "844--855",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "4",

}

TY - JOUR

T1 - Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel

T2 - Systematic review and meta-analysis of individual patient data

AU - Reny, Jean Luc

AU - Fontana, Pierre

AU - Hochholzer, Willibald

AU - Neumann, Franz Josef

AU - ten Berg, Jurriën

AU - Janssen, Paul W.

AU - Geisler, Tobias

AU - Gawaz, Meinrad

AU - Marcucci, Rossella

AU - Gori, Anna Maria

AU - Cuisset, Thomas

AU - Alessi, Marie Christine

AU - Berdagué, Philippe

AU - Gurbel, Paul A.

AU - Yong, Gerald

AU - Angiolillo, Dominick J.

AU - Aradi, D.

AU - Beigel, Roy

AU - Campo, Gianluca

AU - Combescure, Christophe

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Prior studies have shown an association between high on-clopidogrel platelet reactivity (PR) and the risk of major adverse cardiovascular events (MACE). However, large intervention trials on PR-tailored treatments have been neutral. The role and usefulness of PR with regard to levels of cardiovascular risk are unclear. We undertook a systematic review and meta-analysis of individual patient data on MACE outcomes (acute coronary syndromes (ACS), ischaemic strokes, and vascular deaths) in relation to PR and its interaction with cardiovascular risk levels. PR was determined using ADP-induced light transmission aggregometry with a primary concentration of 20 µM ADP. Thirteen prospective studies totaled 6,478 clopidogrel-treated patients who experienced 421 MACE (6.5 %) during a median follow-up of 12 months. The strength of the association between the risk of MACE and PR increased significantly (p=0.04) with the number of risk factors present (age> 75 years, ACS at inclusion, diabetes, and hypertension). No association was detected in patients with no risk factor (p=0.48). In patients presenting one risk factor, only high-PR was associated with an increased risk of MACE (HR 3.2, p=0.001). In patients presenting ≥ 2 risk factors, the increase of risk started from medium-PR (medium-PR: HR=2.9, p=0.0004; high-PR: HR=3.7, p=0.0003). PR allowed the re-classification of 44 % of the total population to a different risk level for the outcome of MACE, mostly in intermediate or high risk patients. In conclusion, the magnitude of the association between PR and MACE risk is strongly dependent on the level of cardiovascular risk faced by patients on clopidogrel.

AB - Prior studies have shown an association between high on-clopidogrel platelet reactivity (PR) and the risk of major adverse cardiovascular events (MACE). However, large intervention trials on PR-tailored treatments have been neutral. The role and usefulness of PR with regard to levels of cardiovascular risk are unclear. We undertook a systematic review and meta-analysis of individual patient data on MACE outcomes (acute coronary syndromes (ACS), ischaemic strokes, and vascular deaths) in relation to PR and its interaction with cardiovascular risk levels. PR was determined using ADP-induced light transmission aggregometry with a primary concentration of 20 µM ADP. Thirteen prospective studies totaled 6,478 clopidogrel-treated patients who experienced 421 MACE (6.5 %) during a median follow-up of 12 months. The strength of the association between the risk of MACE and PR increased significantly (p=0.04) with the number of risk factors present (age> 75 years, ACS at inclusion, diabetes, and hypertension). No association was detected in patients with no risk factor (p=0.48). In patients presenting one risk factor, only high-PR was associated with an increased risk of MACE (HR 3.2, p=0.001). In patients presenting ≥ 2 risk factors, the increase of risk started from medium-PR (medium-PR: HR=2.9, p=0.0004; high-PR: HR=3.7, p=0.0003). PR allowed the re-classification of 44 % of the total population to a different risk level for the outcome of MACE, mostly in intermediate or high risk patients. In conclusion, the magnitude of the association between PR and MACE risk is strongly dependent on the level of cardiovascular risk faced by patients on clopidogrel.

KW - Cardiovascular diseases

KW - Clopidogrel

KW - Drug response

KW - Ischaemic events

KW - Platelets

UR - http://www.scopus.com/inward/record.url?scp=84964786023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964786023&partnerID=8YFLogxK

U2 - 10.1160/TH15-09-0742

DO - 10.1160/TH15-09-0742

M3 - Article

C2 - 26607655

AN - SCOPUS:84964786023

VL - 115

SP - 844

EP - 855

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 4

ER -